Compare Grab Holdings Ltd. (GRAB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs IDEXX Laboratories, Inc. — how do they compare? Grab Holdings Ltd. trades at $3.69 (market cap $15.62B), while IDEXX Laboratories, Inc. trades at $576.42 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.8× Grab Holdings Ltd.'s market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| GRAB | IDXX | |
|---|---|---|
Market Cap | $15.62B | $43.94B |
Sector | Technology | Health |
52-Week High | $6.45 | $766.68 |
52-Week Low | $3.27 | $514.61 |
Enterprise Value | $11.32B | $44.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.715, down 2.24% today, with a bullish technical signal from moving averages. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing significant improvement from previous losses. Revenue grew to $3.37B in 2025, with strong analyst consensus of 11 buys versus 1 sell. Recent news includes CEO share sales and Uber CEO's board departure, creating some investor uncertainty despite positive earnings beats.
GRAB presents a compelling turnaround story with recent profitability and strong growth prospects in Southeast Asian markets. The stock trades at a discount to the $5.45 consensus target, offering 47% upside potential. Key risks include competitive pressures, execution challenges in expanding financial services, and insider selling activity. The company's improving cash flow and debt management support the bullish analyst outlook.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
